Dierssen M, Fructuoso M, Martínez de Lagrán M, Perluigi M, Barone E.
Front Neurosci. 2020 Jul 8;14:670. DOI: 10.3389/fnins.2020.00670
Considering that DS subjects are at high risk to develop either peripheral or brain metabolic defects, this review discuss current knowledge about the link between trisomy of HSA21 and defects of insulin and insulin-related pathways in DS. Drawing the molecular signature underlying these processes in DS is a key challenge to identify novel drug targets and set up new prevention strategies aimed to reduce the impact of metabolic disorders and cognitive decline.